On 7 September 2026, Medcaptain Medical Technology Co., Ltd. (Medcaptain, 2041.HK) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 600 million. CBI is honored to participate in the due diligence work for this IPO Project.

Medcaptain is a China-based company principally engaged in the provision of medical device products. The Company operates its business through three segments. The Life Support Product segment provides complete integration of advanced infusion equipment, anesthesia equipment, and associated consumables. The Minimally Invasive Intervention Product segment provides medical devices designed for endoscopic procedures. The In Vitro Diagnostic (IVD) Medical Device segment provides seamlessly integrated cutting-edge medical testing equipment with tailored reagents.

In this IPO project, CBI primarily assisted the sponsor team in conducting site visits to the company’s customers and coordinating various parties to participate in remote due diligences. The entire due diligence project covered 13 countries and regions, including Peru, Mexico, Brazil and Colombia, etc.